Arixa Pharmaceuticals Completes $8 Million Seed Funding to Initiate Clinical Trial of Oral Avibactam Prodrug to Treat Drug-resistant Gram-negative Infections
Home » Arixa Pharmaceuticals Completes $8 Million Seed Funding to Initiate Clinical Trial of Oral Avibactam Prodrug to Treat Drug-resistant Gram-negative Infections